Beginning in seven months, the new federal legislation will make Canadians with some mental illnesses, including treatment-resistant depression, eligible for medical assistance in dying (MAiD). However, the government is urged to consider amending the Controlled Drugs and Substances Act to allow psychedelic-assisted therapies, such as psilocybin therapy, which has shown promising results in treating mental illnesses.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
